CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma - Escudier, B; Sharma, P; McDermott, DF (Eur Urol, 2017)
et al.